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Based on clinical presentation, glioblastoma (GBM) is stratiﬁed into
primary and secondary types. The protein 53 (p53) pathway is func-
tionally incapacitated in most GBMs by distinctive type-speciﬁc
mechanisms. To model human gliomagenesis, we used a GFAP-
HRasV12mouse model crossed into the p53ERTAM background, such
that either one or both copies of endogenous p53 is replaced by
a conditional p53ERTAM allele. The p53ERTAM protein can be toggled
reversibly in vivo betweenwild-type and inactive conformations by
administration or withdrawal of 4-hydroxytamoxifen (4-OHT), re-
spectively. Surprisingly, gliomas that develop in GFAP-HRasV12;
p53+/KI mice abrogate the p53 pathway by mutating p19ARF/
MDM2 while retaining wild-type p53 allele. Consequently, such
tumors are unaffected by restoration of their p53ERTAM allele. By
contrast, gliomas arising in GFAP-HRasV12;p53KI/KI mice develop in
the absence of functional p53. Such tumors retain a functional
p19ARF/MDM2-signaling pathway, and restoration of p53ERTAM
allele triggers p53-tumor–suppressor activity. Congruently, growth
inhibition upon normalization of mutant p53 by a small molecule,
Prima-1, in human GBM cultures also requires p14ARF/MDM2 func-
tionality. Notably, the antitumoral efﬁcacy of p53 restoration in
tumor-bearing GFAP-HRasV12;p53KI/KI animals depends on the du-
ration and frequency of p53 restoration. Thus, intermittent expo-
sure to p53ERTAM activity mitigated the selective pressure to
inactivate the p19ARF/MDM2/p53 pathway as a means of resis-
tance, extending progression-free survival. Our results suggest that
intermittent dosing regimes of drugs that restore wild-type tumor-
suppressor function onto mutant, inactive p53 proteins will prove
to be more efﬁcacious than traditional chronic dosing by similarly
reducing adaptive resistance.
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Glioblastoma (GBM) is the commonest and most lethal typeof central nervous system neoplasm. Historically, GBMs are
classiﬁed as primary and secondary glioblastomas, the latter
developing from preexisting lower-grade astrocytic tumors. De-
spite their broadly similar tumor histopathologies, the genetics of
human GBM is extremely diverse. Most GBMs appear to be
driven by promiscuous activation of the rat sarcoma (Ras) sig-
naling pathway, either through mutation/overexpression of receptor
tyrosine kinases (1) or through inactivation of neuroﬁbromatosis
(NF1) (2).
The protein 53 (p53) tumor-suppressor pathway is functionally
inactivated in almost all types of human cancer and seems to be a
necessary condition for oncogenic activation. Intriguingly, how-
ever, the mechanism by which p53-mediated tumor suppression is
forestalled varies in differing tumor types. For example, in co-
lorectal, breast, and lung carcinomas, p53 itself is inactivated, ei-
ther by gene loss or through structural mutation (3–5). In contrast,
p53 often remains functionally competent in other cancer types,
but its activation is blocked by mutations that incapacitate trans-
duction of its upstream activating signals. Thus, overexpression or
ampliﬁcation of mouse double minute (mdm2), the gene encoding
the E3-ubiquitin ligase that targets p53 for degradation by the
proteasome, is frequent in prostate cancer, whereas overexpression
of the p53 transcriptional inhibitor MdmX is common in retino-
blastoma (6, 7). In some breast, brain, and lung tumors, the up-
stream inhibitor of Mdm2 activity, p14ARF, is inactivated by gene
loss, methylation, or repression (8–12), thus uncoupling p53 acti-
vation from oncogenic signaling (13, 14). Finally, in tumors asso-
ciated with DNA tumor viruses such as HPV, simian vacuolating
virus 40, and adenovirus, p53 typically is inactivated directly by
viral oncoproteins.
The p53 pathway is functionally inactivated in almost all in-
stances of GBM. However, direct inactivation of p53 itself is rel-
atively rare in primary GBM (15); instead, the p53 pathway is
compromised by deletion of the Ink4a/p14ARF locus or by ampli-
ﬁcation ofmdm2. In contrast, mutations that directly inactivate or
delete p53 itself are the norm in secondary GBM (16). More re-
cent genome-wide systems analyses based on their transcriptome
proﬁles have stratiﬁed gliomas into four molecular signatures:
proneural, neural, classic, and mesenchymal (2). Although both
oncogenic Ras signaling and inactivation of the p53 pathway are
features common to GBMs of all four molecular genetic sub-
groups, the precise mechanism by which Ras is activated and p53
activation is curtailed varies among the four subtypes. Such dif-
ferences presumably reﬂect the differing evolutionary ontogenies
of each GBM subtype. These, in turn, intimate that therapeutic
strategies may need to be tailored to each form of GBM (17).
Indeed, O6-methylguanine-methyltransferase (MGMT) status (18,
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19), isocitrate dehydrogenase (IDH1/2) mutation (20), EGF re-
ceptor (EGFR) ampliﬁcation (21), and p53 status (22) are all
being assessed currently as potential determinants of personal-
ized GBM therapy.
Several strategies for functional restoration of defective p53
pathway signaling in cancers have been proposed, including virus-
mediated delivery of wild-type p53 in tumors that have lost p53
itself, inhibition of Mdm2 and/or MdmX in tumors that retain
functional p53 but in which the activating signal has been disrupted,
and, in tumors with inactivating structural mutations in p53, small
molecules that restore wild-type p53 conformation (23–25). In
GBM the standard of care—irradiation and temozolomide—is
only moderately effective, and additional approaches are being
evaluated (26–28), including restoration of p53 function. How-
ever, the therapeutic efﬁcacy of speciﬁc p53-restoration ther-
apies remains unclear. Clearly, the precise strategy for p53
restoration in any given glioblastoma will need to be tailored to the
mechanism by which the pathway has been disrupted. Even then,
two caveats remain. First, restored p53 function will be thera-
peutically effective only if GBMs harbor both sustained and ob-
ligate p53-activating signals and if they retain intact downstream
p53 effector growth arrest and apoptotic functions. Second, any
approach to p53 functional restoration is susceptible to defeat by
secondary mutations in the restored p53 pathway. How often such
secondary mutations drive relapse depends on the type of muta-
tion responsible for secondary p53 pathway inactivation, itself a
consequence of the initial mechanism of p53 pathway inactivation,
on the spontaneous frequency with which such mutations arise
within the tumor cell population, and on how such secondary
mutations fair under the selective pressure imposed by the initial
p53 restoration.
In this study, we use a preclinical model of GBM in combi-
nation with a switchable p53 allele to model the therapeutic
effect of p53 pathway restoration. We show that the therapeutic
efﬁcacy of p53 pathway restoration is greatly inﬂuenced by both
the initial mechanism of p53 pathway-inactivating mutation and
by the temporal manner in which the selective pressure elicited
by p53 pathway restoration is applied.
Results
p53 Deﬁciency Accelerates Initiation of Harvey RasV12-Driven
Gliomagenesis. We modeled gliomagenesis in vivo using GFAP-
Harvey Ras (HRas)V12 animals, 50% of which develop tumors
that are histopathologically similar to human astrocytomas by age
12 wk, with a lifetime incidence of 95% (29). Although mutant
V12Ha-Ras is not prevalent in human GBMs, this well-established
model exhibits MAPK pathway activation at a level comparable
with human GBMs (29–32), suggesting that the levels of
Ras pathway signaling in the GFAP-HRasV12 mouse model are
not supraphysiological. To assess the contribution of a func-
tional p53 pathway to the suppression of HRasV12-induced
gliomagenesis, hemizygous GFAP-HRasV12 mice were crossed
into the p53KI/KI [knock-in (KI)] background in which the
endogenous p53 gene has been replaced by one encoding the
p53ERTAM [estrogen receptor (ER)] fusion protein. p53ERTAM is
functional only in the presence of the synthetic steroid ligand
4-hydroxytamoxifen (4-OHT). In the absence of 4-OHT, p53KI/KI
mice are functionally p53null (33) but are rapidly, systemically, and
reversibly shifted to p53wt upon systemic administration of ta-
moxifen (TAM), which is metabolized in vivo to 4-OHT. GFAP-
HRasV12;p53KI/KI, GFAP-HRasV12;p53+/KI, and GFAP-HRasV12;
p53+/+ mice were monitored daily from birth for neurological
deﬁcits indicative of astrocytoma development, including ab-
normal movement and tone, hunching, and hydrocephalus. Af-
fected animals were sacriﬁced, brain tissue was harvested, and
the presence of astrocytoma was conﬁrmed by H&E staining
and immunohistochemistry using the glial marker GFAP to-
gether with Ki67 as a marker of proliferation.
The mean latency of tumor formation inGFAP-HRasV12;p53+/+
animals was 17 wk, falling to 16 wk in GFAP-HRasV12;p53+/KI
heterozygous mice and to 9 wk in GFAP-HRasV12;p53KI/KI animals
(Fig. 1A). Despite these signiﬁcant differences in latency, however,
tumors arising from each of the different p53 backgrounds exhibi-
ted very similar pathological features, all closely resembling high-
grade gliomas in human patients (Fig. 1B). The high-grade gliomas
arising in GFAP-HRasV12;p53+/KI and GFAP-HRasV12;p53KI/KI
mice exhibited increased cell density, nuclear polymorphism, in-
ﬁltrating edges, regions of tissue necrosis, and a high Ki67-labeling
index (Fig. 1B). Although the overall frequency of tumors among
the differing p53 backgrounds was similar, p53-deﬁcient animals
exhibited accelerated formation of high-grade gliomas relative to
p53 wild-type and p53 hemizygous backgrounds (Fig. 1C). Hence,
a functional p53 pathway retards the evolution of HRasV12-driven
glial tumorigenesis.
Fig. 1. Loss of p53 accelerates HRasV12-
induced gliomagenesis. (A) Survival plot (in
weeks after birth) of GFAP-HRasV12 (G-Ras)
animals from various p53 backgrounds. The
size of cohorts is indicated. Statistical anal-
ysis was performed using a Mantel–Cox test.
*P < 0.01 for GFAP-HRasV12;p53KI/KI vs.
GFAP-HRasV12;p53+/+ and GFAP-HRasV12;
p53KI/KI vs. GFAP-HRasV12 ;p53KI/+; ns, no
statistically signiﬁcant (difference was de-
tected in survival of GFAP-HRasV12;p53+/+
vs. GFAP-HRasV12;p53KI/+ animals. (B) Exam-
ples of H&E images of high-grade tumors
arising in GFAP-HRasV12;p53KI/+ and GFAP-
HRasV12;p53+/+ genetic backgrounds. Tumors
exhibit increased cell density (I, II), nuclear
polymorphism (III, IV), inﬁltrative edges (V,
VI), areas of tissue necrosis (VII, VIII), and
high Ki6- labeling index (IX, X). [Scale bars:
25 (III, IV), 75 (VII, VIII), 100 (V, VI), and 200 μm
(I, II, IX, X)]. (C) A schematic representation of
the onset and classiﬁcation of tumors that
developed in GFAP-HRasV12 animals of dif-
ferent p53 genotypes.
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HRasV12-Induced Gliomas Arising in p53-Competent Mice Retain
Functional p53 but Inactivate the p53 Pathway Upstream. GFAP-
HRasV12;p53+/KI heterozygous mice harbor one wild-type and
one 4-OHT–dependent copy of p53. Hence, in the absence of
4-OHT, such mice have only a single copy of p53. In other tumor
models loss of the remaining functional p53 allele in both p53+/−
and p53+/KI animals is by far the most common mechanism of
p53 pathway inactivation (34–37). For example, Eμ-myc–driven
lymphomas arising in p53+/KI mice invariably inactivate the wild-
type copy of p53, and subsequent restoration of the second,
4-OHT–dependent p53ERTAM allele triggers dramatic p53-
dependent apoptosis and tumor regression and signiﬁcantly extends
overall survival (37).
We reasoned that if the single wild-type p53 allele is inactivated
during GFAP-HRasV12;p53+/KI tumor progression, then restora-
tion of the remaining conditional p53ERTAM allele to wild-type
function should impact tumor maintenance and subsequent pro-
gression. To address this notion, TAM, which is metabolized to
the active 4-OHT ligand in vivo, was administered to symp-
tomatic GFAP-HRasV12;p53+/KI animals to restore p53 func-
tion, and the impact on survival was monitored. Surprisingly,
restoration of function to the p53ERTAM allele afforded no
signiﬁcant beneﬁt in overall survival (Fig. 2A) and had no dis-
cernible negative impact in vivo on either the viability or pro-
liferation of cells in GFAP-HRasV12;p53+/KI brain tumors (Fig. 2
B and C) despite expression of the p53ERTAM fusion protein in
tumor tissue (Fig. S1A). Consistent with this ﬁnding, the resto-
ration of p53 activity in explanted tumors in vitro by 4-OHT did
not affect the proliferation nor viability of tumor cells (Fig. 2F)
or the expression of bona ﬁde p53 target genes (Fig. S1B).
Although one possible explanation for the lack of impact
of TAM in GFAP-HRasV12;p53+/KI tumors is that the 4-OHT–
dependent p53ERTAM allele had been inactivated in some way,
it also is possible that the gliomas lack a requisite signal to acti-
vate p53ERTAM once it has been functionally restored by TAM.
In the latter scenario, functionally restored p53ERTAM still
should cause growth arrest and/or apoptosis in response to some
other signal, for example, DNA damage (Fig. 2D). To determine
the status of both p53 and p53ERTAM in tumors arising in GFAP-
HRasV12;p53+/KI mice, tumor-bearing animals were exposed to
7 Gy of γ-radiation to activate p53 directly. As a comparison, we
also irradiated tumor-bearing p53KI/KI mice, which are totally
deﬁcient for p53 activity in the absence of TAM. Tumors from all
irradiated animals then were analyzed for DNA damage-induced
apoptosis by immunohistochemical staining for activated caspase
3 (Fig. 2E). Radiation-induced apoptosis was absent from tumors
derived from GFAP-HRasV12;p53KI/KI mice treated with vehicle
control but was evident once p53ERTAM had been functionally
restored by administration of TAM, thus conﬁrming that such
apoptosis is p53 dependent (Fig. S1C). Radiation-induced apo-
ptosis (3.75% of total tumor cells) was evident in the gliomas
arising in GFAP-HRasV12;p53+/KI mice irrespective of whether
TAM was administered, indicating that the wild-type p53 allele
was still functional (Fig. 2E). Similarly, radiation-induced apo-
ptosis and the induction of p53 target genes was apparent in cul-
tured glioma cells derived from p53+/KI mice irrespective of
4-OHT (Fig. 2G) but not in the wild-type p53-deﬁcient tumor
cells from p53KI/KI mice. In the latter case, both apoptosis and
post-irradiation induction of the p53 target genes puma and
cyclin-dependent kinase inhibitor 1a CDKN1A were evident only
when 4-OHT was added to the medium (Fig. S1 D and E). Thus,
the p53-dependent, DNA damage-induced apoptotic pathway
remains intact in GFAP-HRasV12;p53+/KI tumors. Furthermore,
DNA sequence analysis conﬁrmed that the wild-type p53 allele
in such tumors harbored no detectable mutations. Hence, gli-
omas arising in GFAP-HRasV12;p53+/KI retain their functional
wild-type p53 allele.
Because p53 in GFAP-HRasV12;p53+/KI tumors remains func-
tional and is responsive to DNA damage, the likely explanation
for its inactivity is the absence of an upstream signal to activate
p53 in response to oncogenic signaling. The principal mediator
of such oncogenic activation of p53 is the tumor suppressor
p19ARF (p14ARF in humans), which is speciﬁcally induced by
aberrantly elevated ﬂux through oncogenes such as Myc and Ras
(38, 39) and acts to antagonize the p53-suppressive action of
Mdm2 (40, 41). This pathway may be incapacitated either
through loss of p19ARF itself or by overexpression of Mdm2 (Fig.
2D). To determine whether the p19ARF/MDM2 regulatory
pathway is functionally compromised in GFAP-HRasV12;p53+/KI
gliomas, we used Nutlin 3, a pharmacological inhibitor of Mdm2,
to probe its functionality. Nutlin 3 induced signiﬁcant apoptosis
in disaggregated tumor cells from two independent GFAP-
HRasV12;p53+/KI tumors irrespective of the presence of 4-OHT
(Fig. 2H). This effect was completely p53 dependent (Fig. S1F).
Likewise, systemic administration of Nutlin 3 in vivo triggered
signiﬁcant apoptosis (13.1% of tumor cells) in tumors arising in
GFAP-HRasV12;p53+/KI mice (Fig. 2I), although not in wild-type
p53-deﬁcient GFAP-HRasV12;p53KI/KI mice, without affecting the
viability of normal astrocytes (Fig. 2I). Moreover, the level of
Mdm2 protein (a target of Nutlin 3) was signiﬁcantly higher in
the disaggregated tumor cells from two independent GFAP-
HRasV12;p53+/+ and two independent GFAP-HRasV12;p53+/KI
tumor-bearing animals than in the astrocytes isolated from
their GFAP-HRasV12 transgene-negative littermates (Fig. 2J).
These observations indicate that the block in p53 activation in
GFAP-HRasV12;p53+/KI tumors lies upstream of p53 andmost prob-
ably within the Ras oncogene-sensing p19ARF/MDM2 pathway.
HRasV12-Induced Gliomas Arising in the Absence of Functional p53
Retain Persistent p53-Activating Signals. The studies described
above all modeled the evolution of gliomas in which sporadic
Ras pathway activation precedes p53 pathway inactivation, and
they show that, when functional p53 itself is present, Ras acti-
vation drives selection that retains functional p53 in favor of
other p53 pathway-inactivating mutations. To model the alter-
native evolutionary path, in which sporadic p53 loss precedes or
coincides Ras activation, Ras-driven gliomas were allowed to
form in GFAP-HRasV12;p53KI/KI mice, which, in the absence of
TAM, are functionally p53 null. To ascertain whether both p53-
activating signals and downstream p53-mediated tumor-sup-
pressor pathways remained competent in such tumors, we used
TAM to restore p53ERTAM functionally and assayed any effects
of such restoration. Indeed, restoration of p53 triggered a dra-
matic drop in tumor cell proliferation—the proportion of ac-
tively proliferating BrdU-positive tumor cells fell from 13.3%
before p53 restoration to 1.1% after p53 restoration (Fig. 3A)—
and also induced widespread apoptosis in tumors (but not in
normal tissue) (Fig. 3B), occasionally resulting in macroscopic
destruction of the tumor mass (Fig. S2). This single transient
restoration of p53, accompanied by marked induction of p53
target genes (Fig. 3C), signiﬁcantly extended the survival of
tumor-bearing GFAP-HRasV12;p53KI/KI mice (17 d vs. 1.8 d in the
non–TAM-treated controls) (Fig. 3D). TAM treatment of mice
(p53ER-Restored) also rapidly led to a reduction in neurological
deﬁcits in animals and increased general health (Movies S1
and S2). Because p19ARF is a crucial upstream regulator of p53
activity, we assayed p19ARF expression in the tumors before
(p53ER OFF) and 24 h after p53 restoration by addition of TAM
(p53ER-Restored). The percentage of the p19ARF-positive cells
in tumors fell from 32.2 to 5.67% following restoration of the
p53ER allele (Fig. 3E). We reasoned that GFAP-HRasV12;p53KI/KI
arising in the absence of functional p53 harbor persistent p53-
activating signals, such as elevated levels of p19ARF, which
antagonize Mdm2. Upon restoration of functional p53, these
p53-activating signals efﬁciently engage p53-mediated tumor-
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suppressor pathways, resulting in the elimination of the p19ARF-
positive cells, presumably by apoptosis. Consistent with this hy-
pothesis, the GFAP-HRasV12;p53KI/KI tumors exhibited elevated
levels of p19ARF expression and reduced levels of Mdm2 ex-
pression compared with GFAP-HRasV12;p53+/KI tumors that
developed under selective pressure to lose p53-activating signals
(Fig. S3).
To ascertain how the selective pressure exerted by p53 resto-
ration drives secondary p53 pathway inactivation in already
established GFAP-HRasV12;p53KI/KI tumors, we restored p53
function in symptomatic 21-d-old GFAP-HRasV12;p53KI/KI mice
and then maintained p53 function for 10 subsequent weeks by
daily injection of TAM (Fig. 4A). At this point, any symptomatic
animals were presumed to harbor secondarily p53-resistant
tumors. To determine whether such resistant tumors retain
functional p53, symptomatic TAM-treated animals were treated
with Nutlin 3 for 48 h to activate any functional p53 present, and
then tumors were harvested and assayed for apoptosis. Nutlin 3
induced apoptosis (7.59% of total tumor cells) in the tumors
(Fig. 4B), conﬁrming that p53 (and its downstream apoptotic
effectors pathway) remains functionally intact.
Because p53 is functional in these tumors, we reasoned again
that its failure to block tumor growth was likely caused by the
interruption of upstream p53-activating signals. Because p19ARF
is the mediator of oncogenic Ras signaling (39, 42), we assayed
p19ARF expression in both previously untreated tumors (p53ER
OFF) and in tumors subjected to sustained restoration of p53 for
10 wk (p53ER-Restored Sustained) (Fig. 4 C and D). The per-
centage of p19ARF-positive cells in the recurrent tumors growing
in the face of sustained p53ERTAM restoration was signiﬁcantly
less than in the untreated GFAP-HRasV12;p53KI/KI tumors (Fig. 4
C and D). Intriguingly, those few tumor cells in which p19ARF
expression was detectable were not actively proliferating cells, as
determined by their Ki67-negative status (Fig. S4), presumably
a consequence of p19ARF-mediated activation of the p53-induced
cell-cycle arrest. Thus, our data suggest that the sustained res-
toration of p53 function in established GFAP-HRasV12;p53KI/KI
tumors selects for the emergence of the p53 pathway-defective
tumor cells. However, such selection evidently is directed at the
Fig. 2. Gliomas arising in p53-competent mice lose upstream p53-activating
pathways. (A) Life span (in days after treatment) of tumor-bearing GFAP-
HRasV12;p53+/KI animals following treatment for 24 h with either vehicle
(p53ER OFF; control) or TAM (p53ER Restored). Cohorts of seven animals per
group were analyzed. Statistical analyses were performed using a two-tailed
Student t test; ns, no statistical signiﬁcance. (B) Immunohistochemical anal-
ysis of apoptosis in tumors derived from GFAP-HRasV12;p53+/KI mice after
treatment for 24 h with either vehicle (p53ER OFF; control) or TAM (p53ER
Restored). Tumor area was determined by increased GFAP staining and cell
density and is outlined by the dashed line. Cell death was assayed by staining
for activated caspase 3. The percentage of caspase 3-positive cells out of all
tumor cells is indicated. The arrow indicates the appearance of an apoptotic
cell in the tumor mass. (Scale bars: 50 μm.) (C) (Left) Immunohistochemical
analysis of cell proliferation status by BrdU incorporation and Ki67 staining
in the tumors described in B. The percentage of BrdU/Ki67-positive cells out
of all tumor cells is indicated. Arrows indicate double-positive cells. (Scale
bars: 20 μm.) (Right) A schematic representation of the regimen for
p53ERTAM allele restoration is shown. A single dose of TAM was adminis-
tered i.p. to symptomatic animals (p53ER Restored), and a single dose of
vehicle was administered to control (Ctrl) animals (p53ER OFF). BrdU was
administered 22 h later, and tissues were harvested 2 h after BrdU admin-
istration. (D) Schematic representation of the p53 tumor-suppressor path-
way. Activated oncogene(s) (and other potential signals) induce expression
from the alternate reading frame (ARF) of the CDKN2A gene, whose
product, p19ARF, stabilizes and activates p53 by blocking the p53 inhibitor
MDM2. Activated p53 then executes its principal tumor-suppressive activi-
ties, i.e., induction of apoptosis and/or growth arrest. Loss of the ARF locus
or up-regulation of MDM2 inactivates the functional p53 pathway. In such
settings, p53 activity might be restored by the induction of an alternative
p53-activating signal (e.g., DNA damage) or by pharmacological inhibition of
MDM2 (e.g., by Nutlin 3). (E) Immunohistochemical analysis of cell death
assayed by staining for activated caspase 3 in GFAP-HRasV12;p53+/KI and
GFAP-HRasV12;p53KI/KI tumors in nonirradiated animals (Ctrl) and in animals
irradiated with 7 Gy(Gy). Arrows indicate apoptotic cells. (Scale bars: 20 μm.)
(F) Cell death depicted as the percentage of total tumor cells in in vitro
tumor cell cultures derived from GFAP-HRasV12;p53+/KI animals after treat-
ment with vehicle (Ctrl), 4-OHT to restore p53 function (4-OHT), and irradi-
ation (7 Gy) in combination with either vehicle treatment (Gy/Ctrl) or p53
restoration (Gy/4-OHT). The data represent experiments on three in-
dependently derived tumors analyzed in triplicate. Cell viability was de-
termined by trypan blue exclusion. ***P ≤ 0.001; **P ≤ 0.01; ns, no statistical
signiﬁcance (statistical analyses were performed using a two-tailed Student
t test). (G) Quantitative RT-PCR (qRT-PCR) analysis of mRNA expression of the
p53 target genes puma and p21cip1 (CDKN1A) in cells cultured in vitro from
tumors of GFAP-HRasV12;p53+/KI animals and after exposure to 7-Gy γ-radi-
ation in combination with 24-h exposure to 4-OHT (Gy/4-OHT) versus vehicle
(Gy/CTRL). The data are presented as fold induction relative to nonirradiated
samples and represent experiments from three independently derived
tumors, each assayed in triplicate. ns, no statistical signiﬁcance (two-tailed
Student t test). (H) Percent of tumor cells undergoing apoptosis (as de-
termined by the trypan blue exclusion method) in vitro after treatment of
either vehicle-treated (dark gray bars) or 4-OHT–treated (light gray bars)
tumor cell cultures derived from GFAP-HRasV12;p53+/KI animals with the
MDM2 inhibitor Nutlin 3 at a concentration of 16 (16 μM Ntl) or 32 (32 μM
Ntl), or with the vehicle for Nutlin treatment (DMSO). The graph represents
experimental data from two tumor cell cultures independently originated
from two different tumors derived from different animals [tumor-145
(T-145) and tumor-890 (T-890)], each analyzed in triplicate. ***P ≤ 0.0001;
**P ≤ 0.001; statistical analyses were performed using one-way ANOVA. (I)
Immunohistochemical analysis of cell death assayed by staining for activated
caspase 3 in tumors from either vehicle-treated (Ctrl)-or Nutlin 3-treated
GFAP-HRasV12;p53+/KI animals. The percentage of caspase 3-positive cells out
of total tumor cells is indicated. The tumor area is outlined. (Scale bars:
20 μm.) (J) Immunoblotting analysis of Mdm2 protein expression in tumor-
derived cell cultures from GFAP-HRasV12;p53+/+ and GFAP-HRasV12;p53KI/+
animals. Two independently derived primary tumor cultures of each geno-
type are presented. Astrocytes isolated from the GFAP-HRasV12-negative
littermates (p53+/+ and p53KI/+, respectively) are used as controls. β-Actin was
used as an equal loading control.
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upstream p19ARF/MDM2 regulators of p53 function and not
against the p53 gene itself.
Optimizing of p53 Restoration Therapy. Our data indicate that re-
storing p53 function can exert a profound initial therapeutic
impact in gliomas that evolve in the absence of functional p53.
However, that therapeutic impact is eroded rapidly by the
emergence of secondarily p53-resistant tumor clades that out-
grow in the face of the selective pressure imposed by p53 res-
toration. It is known that both the rate at which adapted species
arise and the evolutionary mechanism by which they do so can be
inﬂuenced profoundly by whether selection is sustained or epi-
sodic (43). Given that sustained p53 restoration in GFAP-
HRasV12;p53KI/KI gliomas drives such rapid emergence of lethal
secondary p53 pathway mutants, we asked how altering the
timing and duration of p53 restoration inﬂuences the emergence
of resistance. To start, we transiently restored p53 function once
in 21-d-old GFAP-HRasV12;p53KI/KI mice by administering a sin-
gle dose of TAM. Surprisingly, even this single short period of
p53 restoration signiﬁcantly extended overall survival (Fig. 5A):
50% of controls died by 45 d compared with 74 d in 4-OHT-
treated animals. Nonetheless, as with sustained TAM-treated
GFAP-HRasV12;p53KI/KI mice, all animals eventually succumbed
to disease.
Relapse after transient p53 restoration might be caused by the
outgrowth of tumor cells harboring mutations that confer re-
sistance to p53ERTAM restoration, in which case the recurring
tumors should be resistant to subsequent p53 restoration. Al-
ternatively, relapse might be caused by the resumed growth
of a subpopulation of tumor cells that, although still sensitive
to p53 restoration, undergo reversible growth arrest instead
of apoptosis. In this latter case, the recurring tumors should
remain responsive to subsequent p53 restoration. To distinguish
between these two possibilities, 21-d-old GFAP-HRasV12;p53KI/KI
mice were subjected to a single, transient p53 restoration, which,
as indicated previously, signiﬁcantly delayed tumor outgrowth.
The animals were monitored daily for neurological deﬁcits in-
dicative of astrocytoma development. Then p53 function was
restored again in the symptomatic (tumor-bearing) GFAP-
HRasV12;p53KI/KI animals, and its impact on tumor apoptosis was
assessed. Intriguingly, the delayed tumors remained responsive
to p53 restoration, exhibiting dramatic p53-dependent apoptosis
(Fig. 5B). However, because GFAP-HRasV12 animals might de-
velop gliomas throughout their lifespan, the possibility existed
that these delayed tumors exhibited p53 sensitivity because they
had arisen de novo rather than surviving outgrowth from the
original tumors. Therefore, to conﬁrm that outgrowths from
original p53-sensitive tumors subjected to transient p53 resto-
ration indeed are sensitive to subsequent p53 restoration, we
transplanted GFAP-HRasV12;p53KI/KI tumors intracranially into
congenic p53KI/KI recipients and then subjected the recipient
animals to a single episode of p53 restoration. Just as in the
autochthonous tumors, the growth of transplanted tumors was
delayed but not prevented (Fig. S5A). Moreover, the reemerging
transplanted tumors remained largely responsive to p53-induced
apoptosis following subsequent restoration of p53ERTAM allele
(Fig. S5B), supporting the notion that a single transient resto-
ration of p53 in tumors does not convey resistance to the suc-
cessive restoration of p53 activity. Hence, unlike tumors evolving
in the presence of sustained p53 restoration, tumors recurring
after a single, transient restoration of p53 function retain re-
sponsiveness to subsequent p53 restoration.
We hypothesized that p19ARF, as the principal mediator of
p53 activation in GFAP-HRasV12 ;p53KI/KI gliomas, also was ex-
pressed in tumors arising after a single transient restoration of
p53. To investigate this hypothesis, we compared expression of
p19ARF in tumors harvested from previously untreated, symp-
tomatic GFAP-HRasV12;p53KI/KI mice (“naive tumors”) and from
animals that succumbed to the disease after a single transient
restoration of p53 at the age of 21 d (1× TAM). The tumor-
bearing animals were injected with BrdU to label actively pro-
liferating cells and were given a control vehicle or a single dose
of TAM 4 h later to restore p53 transiently. Both naive tumors
and tumors that reemerged after a single exposure to TAM at
the age of 21 d contained p19ARF;BrdU double-positive cells
(36.4% and 30.2% respectively) before transient restoration of
p53 activity (Fig. 5C). The percentage of p19ARF;BrdU double-
positive cells dropped signiﬁcantly (8.6% and 6.98%, respectively)
20 h after restoration of p53 function (p53ER-Restored), sug-
gesting that most of the actively proliferating p19ARF-positive
cells in both naive tumors and tumors arising in animals after
transient p53 restoration (1× TAM) presumably are eliminated
by apoptosis when p53 is restored for 24 h (p53ER Restored).
Moreover, any remaining p19ARF-positive cells still present in
both the naive and 1× TAM tumors were all Ki67 negative (Fig.
5D), indicating their growth arrest.
Having established that tumors recurring after a single, tran-
sient restoration of p53 remain largely responsive to a second
round of p53 restoration, we next asked whether repeated, in-
Fig. 3. Gliomas arising in the absence of functional p53 retain persistent
p53-activating signals. (A) (Left) Immunohistochemical analysis of cell pro-
liferation in GFAP-HRasV12;p53KI/KI tumors assayed by BrdU incorporation
and Ki67. A single i.p. injection of TAM (p53ER Restored) or vehicle (p53ER
OFF) was administered to symptomatic GFAP-HRasV12;p53KI/KI animals, and
22 h later the animals were injected i.p. with BrdU. Tissue samples were
harvested 2 h later. Arrowheads indicate arrested, BrdU-positive/Ki67-negative
cells in 4-OHT–treated tumors. (Scale bars: 50 μm.) (Right) A schematic repre-
sentation of the regimen for p53ERTAM allele restoration. (B) Immunohisto-
chemical analysis of apoptosis in tumors after 24-h p53ERTAM restoration in
symptomatic GFAP-HRasV12;p53KI/KImice. Lateral ventricles (LV) and tumor area
(T) are indicated. Cell death was assayed by staining for activated caspase 3,
and the percentage of total tumor cells that are caspase 3 positive cells is in-
dicated. (Scale bars: 100 μm.) (C) qRT-PCR analysis of mRNA expression of the
p53 target genes CDKN1A, puma, andmdm2 in tumor-derived cell cultures
from GFAP-HRasV12;p53KI/KI animals after 24-h exposure to 4-OHT in vitro.
Data are presented as fold induction relative to vehicle-treated control
samples and represent experiments on three independently derived tumors,
each analyzed in triplicate. (D) Life spans (in days after treatment) of tumor-
bearing GFAP-HRasV12;p53KI/KI animals after 24-h treatment with either
vehicle (p53ER OFF) or TAM (p53ER Restored). Cohorts of seven animals per
group were analyzed. Statistical analyses were carried out using a two-tailed
Student t test. (E) Immunohistochemical analysis of p19ARF expression
in previously untreated tumors (p53ER-OFF) compared with tumors sub-
jected to a single TAM treatment 24 h before the sample collection (p53ER-
Restored). (Scale bars: 20 μm.)
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termittent transient p53 restoration in GFAP-HRasV12;p53KI/KI
mice might confer a therapeutic advantage over sustained p53
restoration. A cohort of 21-d-old GFAP-HRasV12;p53KI/KI ani-
mals was subjected to transient p53 restoration (a single TAM
injection) once a week for 10 wk. Remarkably, more than 80% of
such intermittently treated mice remained symptom-free, sur-
viving beyond 100 d (Fig. 5E).
The signiﬁcant survival beneﬁt afforded by intermittent tran-
sient p53 restoration over sustained p53 restoration suggests
that, as with tumors remerging after single transient p53 resto-
ration at age 21 d (1× TAM), the tumors retain p53 sensitivity
throughout subsequent rounds of p53 restoration. To conﬁrm
this possibility, we assayed induction of apoptosis after repeated
rounds of p53 restoration. Seven-week-old asymptomatic ani-
mals previously subjected either to a single dose of TAM at age
21 d (1× TAM) or to three sequential rounds of treatment with
TAM once a week, starting on day 21 and with the last injection
occurring at age 5 wk (Intermittent TAM), were treated with
TAM (p53ER-Restored). Tissues were harvested 24 h after the
last p53 restoration. After the transient restoration of p53 ac-
tivity we detected similar levels of apoptosis in the lesions (8.8%
and 6.8%, respectively) (Fig. 5F).
Because the presence of a functional p19ARF/MDM2 regulatory
branch is crucial for oncogenic activation of p53 tumor-suppressor
response, we ascertained the status of p19ARF expression in tumors
subjected to intermittent restoration of p53. Brain samples for
analysis were collected from 7-wk-old asymptomatic animals pre-
viously treated with a single dose of TAM at age 21 d (1× TAM)
or with three sequential rounds of TAM once a week starting at
age 21 d, with the last injection occurring at 5 wk of age (In-
termittent TAM). Notably, and in contrast to the tumors re-
emerging during sustained restoration of p53 (Fig. S4), tumors
reemerging in animals subjected to a single transient restoration
of p53 at age 3 wk and those reemerging in animals after re-
peated intermittent p53 restoration retained p19ARF expression
in actively proliferating, Ki67-positive tumor cells (Fig. S6).
Taken together, these data indicate that, unlike sustained res-
toration of p53, the repeated transient imposition of p53 resto-
ration negates the otherwise strong selective advantage afforded
by p53-pathway ablation in gliomas arising in GFAP-HRasV12;
p53KI/KI mice, thereby signiﬁcantly enhancing the durability of
the therapeutic response to p53 restoration.
Restoration of p53 Activity in Human Glioma Cultures. The GFAP-
HRasV12;p53+/KI and GFAP-HRasV12;p53KI/KI mouse models of
gliomagenesis mimic two different scenarios of human glioma
progression. In both, the p53 pathway is incapacitated. In GFAP-
HRasV12;p53+/KI mice, Ras activation precedes p53 pathway in-
activation, and functional p53 is retained in favor of mutations
that inactivate the upstream p53-activating signal. In contrast,
in the GFAP-HRasV12;p53KI/KI mouse model, in which loss of
p53function (resulting from the absence of 4-OHT) precedes or
coincides with Ras activation, both upstream p53-activating sig-
nals and downstream p53-mediated arrest and apoptotic path-
ways remain intact. Only in this latter case would restoration of
p53 function be expected to have any growth-suppressive effect.
Notably, these distinctive mouse models phenocopy the two
predominant modes of p53 pathway disruption in high-grade
human gliomas: 42% retain functional p53 and lose ARF
(p53WT;CDKN2A (ARF) MT), whereas ∼20% inactivate p53
directly and retain ARF (p53MT; CDKN2A(ARF) WT) (refs. 2
and 17 and Fig. 6A).
To model the therapeutic impact of p53 restoration in human
gliomas of each class, we exposed human GBM cell lines (44) to
2, 2- bis(hydroxymethyl)- 3- quinuclidinone (Prima-1), a small-
molecular-weight compound that restores the defective conforma-
tion of mutant p53, rescuing competence for both DNA binding
and activation of p53 target genes (45). Human GBM cell lines
carrying either wild-type p53 (p53WT) or mutated copies of
p53 (p53MT) in combination with either competent CDKN2A
(CDKN2A WT) or deleted CDKN2A (CDKN2A MT) were ex-
posed to Prima-1 (5, 10, or 20 μM) or control vehicle for a period
of 1, 3, or 5 d, and effects on cell proliferation and p53 target gene
induction were ascertained. At the concentration used (20 μM),
Prima-1 elicited only minor p53-independent effects (prolif-
eration of p53WT tumors fell by 14% upon Prima-1 exposure)
(Fig. 6B). In contrast, Prima-1 exposure induced signiﬁcant
growth inhibition (98% reduction in cell proliferation) in glioma
cells harboring mutant p53, but only if they also retained
CDKN2A(ARF) (Fig. 6B). The antiproliferative effect of Prima-1
coincided with the induction of p53 target genes [CDKN1A
(p21cip1), mdm2, and growth arrest and DNA damage gene 45a
(gadd45a)] (Fig. 6C). This increased sensitivity of CDKN2A
(ARF)-competent GBM cells to Prima-1 as compared with
CDKN2A-deﬁcient GBM cells was conﬁrmed by analysis of an
independent set of human primary GBM cultures (Fig. S7). Our
data suggest that in human GBMs, as in gliomas arising in
GFAP-HRasV12;p53KI/KI mice, the presence of functional p53-
activating signals is crucial to educe the p53 tumor-suppressor
activities upon p53 restoration.
We next sought to determine whether in human GBM cell
lines intermittent reactivation of p53 circumvents acquired
resistance to p53-restoration therapy, similar to effect of in-
termittent p53 reactivation in the conditional mouse model. We
propagated human GBM cell lines harboring mutant p53 but
wild-type CDKN2A(ARF) in the presence of sustained or in-
Fig. 4. Sustained restoration of p53ERTAM in mouse gliomas promotes the
emergence of resistant tumor variants. (A) Survival curves (in days after
birth) of GFAP-HRasV12;p53KI/KI animals subjected to daily treatment with
vehicle (CTRL, black lines and squares) or to sustained restoration of
switchable p53 (Sustained, purple lines and circles). The arrow indicates
initiation of treatment. The dotted line indicates the duration of the treat-
ment. *P < 0.01. The statistical analysis was performed using the Mantel–Cox
test. (B) Immunohistochemical analysis of apoptosis as determined by acti-
vated caspase 3 in tumors collected from GFAP-HRasV12;p53KI/KI animals 24 h
after the last daily injection with 4-OHT to sustain restoration of switchable
p53ER. The animals were treated with the Mdm2 inhibitor Nutlin 3 or with
vehicle (Control) as described inMaterials and Methods. The tumor area and
the percentage of caspase 3-positive cells in tumors are indicated. (Scale
bars: 50 μm.) (C) Immunohistochemical analysis of p19ARF expression in
previously untreated tumors (p53ER-OFF) and in tumors that developed
under sustained p53ERTAM restoration (p53ER-Restored-Sustained). Analysis
of p19ARF expression in tumors following 24-hour p53ERTAM restoration
(p53ER-Restored-24 hrs) is provided as a control. (Scale bars: 50 μm.) (D) A
graphical representation of the quantiﬁcation analysis of p19ARF-positive
cells exempliﬁed in Fig. 4C is presented as the percentage of total tumor
cells. At least four animals were analyzed for each treatment. Immunohis-
tochemical analysis was performed in duplicate; 10 randomized ﬁelds per
staining were considered. ***P ≤ 0.001; ns, no statistical signiﬁcance. Sta-
tistical analyses were performed using a two-tailed Student t test.
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termittent exposure to Prima-1 at two different concentrations
(10 and 20 μM) for a duration of 7 wk. At the end of the
treatment, the cells were allowed to expand in Prima-1–free
medium for an additional week. The resulting “sustained” and
“intermittent” cultures were exposed to 0, 5, 10, and 20 μM of
Prima-1 for 72 h, and effects on cell proliferation were measured.
Reintroduction of Prima-1 induced a signiﬁcant reduction of
proliferation in GBM cultures that were propagated under in-
termittent exposure to Prima-1 but not in cultures subjected to
sustained exposure to Prima-1 (Fig. 6D). This resistance of hu-
man GBM cells to chronic Prima-1 exposure was characterized
by the loss of CDKN2A(ARF) mRNA and protein expression
(Fig. 6 E and F). Our data show that in human GBM cell lines, as
in the GFAP-HRasV12;p53KI/KI mouse model, transient exposure
to p53 activity signiﬁcantly prolongs therapeutic response to
a treatment aimed to restore p53 function.
Discussion
Emerging evidence suggests that primary and secondary GBMs
exhibit different patterns of genetic alterations, reﬂecting their
distinct etiologies and potentially inﬂuencing their responsive-
ness to certain therapies, in particular therapies targeting speciﬁc
molecular pathways (22). Alterations that diminish or abrogate
the functions of the p53 tumor-suppressor pathway are seen in
both primary and secondary GBM. However, p53 pathway dys-
function arises by different mechanisms in each of the two GBM
subtypes. Loss of p53 itself through inactivating mutations is an
early event in the multistep development of about two thirds of
secondary GBM (46). In contrast, in primary GBM the p53 tu-
mor-suppressor pathway is incapacitated most frequently by the
deletion of the Ink4/ARF locus or by overexpression of MDM2,
rather than by loss or mutational inactivation of p53 itself (15,
16, 47).
Using mice in which theGFAP-HRasV12 transgene is combined
with either hemi- or homozygosity for a conditional allele of p53
(p53KI/KI), we modeled the evolution of these two distinct sub-
types of gliomas and ascertained the therapeutic potential of p53-
based therapy in each. Although human GBMs rarely display
HRasv12 mutations, the elevated activity of constitutively ex-
pressed HRasV12 produces elevated levels of MAPK pathway
activation comparable to those observed in human GBMs with
either EGFR or PDGF receptor A/B (PDGFR-A/B) ampliﬁca-
tion and/or activating mutations, which are common driver on-
cogenic mutations in human GBM (31, 48). GFAP-HRasV12;
p53KI/KI mice, in which p53 is inactive throughout Ras-induced
gliomagenesis, mimic the evolution of human gliomas wherein
p53 itself is inactivated at the outset of tumor progression. We
observed that the absence of functional p53 signiﬁcantly accel-
erated Ras-induced gliomagenesis, consistent with the recently
demonstrated role played by p53 inactivation in the progression
of astrocytomas in humans (49). Functional restoration of p53 in
such tumors triggered immediate p53 activation, arrest of tumor
cell growth, and apoptosis, indicating that both upstream p53-
activating signals and downstream tumor-suppressor effectors for
apoptosis and growth arrest remained intact when p53 function
was missing throughout tumorigenesis. By analogy, we predict
that p53-restoration therapies are likely to be efﬁcacious in hu-
man GBM in which p53 is inactivated early in tumor evolution.
In contrast, malignant astrocytomas developing in GFAP-
HRasV12;p53+/KI mice (in which one p53 allele is wild type)
Fig. 5. Optimizing of p53-restoration therapy. (A) Survival
curve (in days after birth) of GFAP-HRasV12;p53KI/KI animals
that were untreated (CTRL. black lines and squares) or sub-
jected to a single dose of TAM to restore p53ERTAM at the age
of 21 d (1× TAM, purple lines and circles). The arrowhead
indicates the time point of treatment. *P < 0.01. Statistical
analysis was performed using the Mantel–Cox test. (B) Immu-
nohistochemical analysis of apoptosis in GFAP-HRasV12;p53KI/KI
tumors detected by the TUNEL assay collected 24 h after ex-
posure to TAM (p53ER-Restored). The tumors presented either
developed from either previously untreated animals (naive) or
were reemerging tumors following a single TAM treatment of
animals at age 21 d (1× TAM). The percentage of TUNEL-
positive cells in tumors is indicated. (Scale bars: 50 μm.) (C and
D) (Left) Analysis of p19ARF expression in BrdU-positive (C) and
Ki67-positive tumor cells (D) in GFAP-HRasV12;p53KI/KI tumors
in previously untreated animals (naive) or reemerging after
a single TAM treatment at age 21 d (1× TAM). The tumor-
bearing animals were injected with BrdU and 4 h later
were injected with vehicle (p53ER-OFF) or with TAM (p53ER-
Restored). The samples were collected 24 h later and were
analyzed. The percentage of p19ARF-positive cells within the
populations of BrdU- and Ki67-positive cells is indicated. The
dotted lines demarcate the areas enlarged in the Insets
showing double-positive cells. (Scale bars: 20 μm.) (Right) A
schematic representation of the treatment. (E) Comparative
survival curves (in days after birth) of control GFAP-HRasV12 ;
p53KI/KI animals (CTRL, black lines and squares) versus a cohort
of mice subjected to repeated p53 restoration once a week
(Intermittent TAM, purple lines and circles). The arrowhead
indicates the initiation of TAM treatment. *P < 0.01. The
dotted line indicates the duration of treatment. One animal
succumbed to thymic lymphoma during the experiment and
was removed from the study. Statistical analysis was performed using the Mantel–Cox test. (F) Immunohistochemical analysis of apoptosis by caspase 3
staining after restoration of the p53ERTAM allele for 24 h (p53ER-Restored) in GFAP-HRasV12;p53KI/KI tumors reemerging in animals after a single treatment
with TAM at age 3 wk (1× TAM), compared with tumors from animals subjected to three rounds of p53 restoration once a week starting at age 3 wk (In-
termittent TAM). The percentage of apoptotic cells in tumor area is indicated. 1× TAM, n = 6; Intermittent TAM, n = 4 treatment. Immunohistochemical
analysis was performed in duplicate; 10 randomized ﬁelds were considered. Lateral ventricles (LV), corpus callosum (cc), and tumor area (T) are indicated.
(Scale bars: 50 μm.)
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model the evolution of human tumors, such as primary GBMs, in
which Ras activation precedes the loss of a functional p53
pathway (13). In such tumors restoration of p53 function is
therapeutically irrelevant, because selection against the p53
pathway preferentially elicits either loss of p19ARF or up-regu-
lation of Mdm2, rather than direct inactivation of p53 protein
itself as observed in the (cis)p53+/−;NF1(+) ﬂox/ﬂox;hGFAP-cre–
positive model (50). These results highlight the mutual comple-
mentarity of the two models. Indeed, human glioblastomas de-
ﬁcient for NF1 activity exhibit relatively low levels of total and
phospho-proteins in the PI3K and MAPK pathways, indicating
oncogene-signaling activity, as compared with GBMs carrying
elevated expression of and/or mutations in EGFR or PDGFR A/
B (48). Although restoration of functional p53 is inconsequential
for p53-competent tumors, activation of p53 by Nutlin 3, an
Mdm2 inhibitor, has been proven to induce cell death in these
tumors (Fig. 2I). For gliomas with wild-type p53 status, either
Nutlin 3 itself or other inhibitors of Mdm2 activity potentially
can be translated into clinical settings. Unfortunately, it is im-
possible to predict whether in these tumors an intermittent
regimen of Mdm2 inhibition in gliomas will be as efﬁcacious as
the intermittent restoration of p53 in the p53-deﬁcient lesion.
The resistance of tumor cells to treatments based on Mdm2 in-
hibition might be achieved by mechanisms other than resistance
to p53 restoration (e.g., Mdm2 ampliﬁcation).
We evaluated the potential impact of p53 restoration in human
GBM cell lines that carry p53 gene mutations by using a small-
molecular-weight molecule, Prima-1, that selectively restores
sequence-speciﬁc DNA-binding activity to mutant forms of p53
protein. As in theGFAP-HRasV12 -driven gliomas, the restoration
of p53 activity inhibited human GBM cell proliferation. However,
as in the GFAP-HRasV12–driven gliomas, the p53 tumor-sup-
pressor activity and the induction of p53 transcriptional targets
following exposure to Prima-1 were detected only in tumors in
which the p53-activating branch (p14ARF/MDM2) remained intact
(Fig. 6 B and C and Fig. S7). Moreover, in human GBM cells the
selective pressure against the p53 pathway imposed by sustained
exposure to Prima-1 results in the loss of p14ARF expression and
subsequent resistance to the drug treatment (Fig. 6D–F). Around
11% of all human GBMs contain mutations in both the p53 gene
and its activating tumor-suppressing branch, p14ARF/MDM2, as
was established recently by the molecular proﬁle of human GBMs
(http://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp and ref. 2). Our
data suggest that restoration of p53 activity by Prima-1 alone [or
by other small molecules modulating the DNA-binding activity of
mutant p53 (51)] is not sufﬁcient to induce p53 tumor-suppressor
activity in these doubly mutant patients, and alternative means of
p53 activation (e.g., DNA damage) should be considered for
therapeutic intervention based on p53 restoration.
Given the prospect of using such p53-restoration therapies in
GBM patients, we went on to use the GFAP-HRasV12;p53KI/KI
model to assess potential regimens for p53 restoration in the
p53-mutant fraction of gliomas. In GFAP-HRasV12;p53KI/KI tu-
mors, sustained restoration of p53 function rapidly selects for
the emergence of tumor cell populations resistant to p53 func-
tion by virtue of abrogating p53-activating signals, i.e., loss of
p19ARF or ampliﬁcation of MDM2. Further analyses established
that there is a signiﬁcant difference between tumors subjected to
sustained p53 restoration and the tumors that developed in
GFAP-HRasV12;p53KI/KI animals after a short-term restoration of
p53 activity. The latter emerge faster (Figs. 4A and 5A) and,
surprisingly, retain p19ARF/MDM2 signaling (Fig. 5B). Thus, it
appears that losing p19ARF does not convey growth or survival
advantage to the Ras-driven tumors that have developed in the
context of inactive p53 until p53 function is chronically restored.
In marked contrast to the resistance mediated by the loss of
p19ARF in chronically p53-restored tumors, the tumors remerging
after a brief period of p53 restoration do not develop such re-
sistance, as evidenced by their susceptibility to undergo apoptosis
and replicative growth arrest subsequently in response to addi-
tional rounds of transient p53 restoration.
Taken together, our data imply the existence of three pop-
ulations within the GFAP-HRasV12;p53KI/KI tumors, each with a
distinct response to p53 restoration. Two of these populations
are sensitive to p53 restoration: one, comprising the bulk of
tumor cells, responds to p53 restoration by apoptosis and/or
permanent replicative arrest. A second, smaller, population also is
responsive to p53 restoration but instead of dying undergoes
viable and reversible replicative arrest. Once p53 function is
removed, this second population regenerates the tumor. Clearly,
the refractoriness of this second population to p53-induced ap-
optosis is not a heritable trait, because the bulk of cells within the
Fig. 6. Pharmacological restoration of p53 activity in human glioma cul-
tures. (A) A pie chart illustrating the proportions of human glioma patients
(http://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp and ref. 2) with differential
status of wild-type or mutated (MT) p53 and wild-type or deleted/mutated
(MT) CDKN2A(ARF). (B) Proliferation (presented as percent of control cul-
tures) of human GBM cell lines (described in Material and Methods) with
differential status of p53 and CDKN2A(ARF), mock-treated (vehicle, dark
gray bars) or treated with 20 μM Prima-1 (Prima-1, light gray bars) for 5 d. (C)
The expression of p53 target genes CDKN1A(p21), mdm2, and gadd45a in
the human glioma cell cultures following treatment with 5 μM Prima-1 for
24 h is presented as the fold expression relative to the control-treated
samples. The expression of the target genes was normalized to ribosomal
protein L13a (RLP13A) gene expression. The differential status of p53 and
CDKN2A (ARF) are indicated. All analyses were performed in triplicate. (D)
Proliferation (presented as percent of vehicle-treated cells) of LN 215 human
GBM cells propagated on the sustained or intermittent regimens of Prima-1
treatment (10 μM) for 7 wk, as described inMaterial and Methods. Cells were
treated with Prima-1 at the indicated concentrations for 72 h, and pro-
liferation was assessed using the Cell Titer GloR luminescent assay. All
experiments were repeated in triplicate. ***P ≤ 0.001 by two-way ANOVA.
Two independent cultures for each treatment (sustained and intermittent)
were generated and analyzed. (E) The expression of p14ARF in LN 215 cells
propagated on the sustained or intermittent regimens of Prima-1 treatment
(10 or 20 μM) for 7 wk as described in Material and Methods is presented
relative to the p14ARF expression in the parental LN 215 cell culture. The
p14ARF expression was normalized to RLP13A gene expression. The asterisk
indicates that p14ARF mRNA expression was below the detection level in the
LN 215 cells propagated in the 20-μM sustained Prima-1 regimen. All anal-
yses were performed in triplicate. (F) (Left) Immunoblotting analysis of
p14ARF protein expression in LN 215 cell cultures propagated as described
above. (Right) p14ARF protein expression in the parental LN 215 cells relative
to HeLa cells. β-Actin was used as a loading control.
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tumors from which it regenerates are, once again, susceptible to
p53-induced apoptosis. Possibly such resistant glioma cells rep-
resent an innately apoptosis-resistant tumor stem cell population
or, alternatively, cancer cells transiently residing in a protected
somatic niche. The trivial possibility that some tumor cells sur-
vive p53 restoration through lack of exposure to 4-OHT seems
unlikely, given the ubiquitous restoration of p53 that we have
observed following systemic administration of 4-OHT to p53KI/KI
mice, the facile capacity of 4-OHT to cross the blood–brain
barrier, and the persistence of 4-OHT in plasma for up to 24 h
following the administration of a single bolus (52, 53). In addi-
tion to these p53-sensitive populations, there evidently is a third
population of tumor cells that harbors a preexisting secondary
p53 pathway-inactivating mutation and that therefore is innately
unresponsive to p53 restoration.
The eventual outgrowth of this third population of p53-
resistant tumor cells and the p53-resistant tumor they regenerate
limits how long survival may be extended by periodic p53 res-
toration. Hence, factors that govern the rate of outgrowth of this
population will be critical in determining the overall therapeutic
efﬁcacy of p53 restoration. Although sustained p53 restoration
affords a selective advantage only to innately p53-resistant tumor
cells, transient p53 restoration (once relaxed) permits the out-
growth of both innately p53 resistant tumor cells and those tu-
mor cells that are only adventitiously refractory to p53-induced
apoptosis. Perhaps competition between these two populations
or the differential activity of Ras signaling in tumor cells miti-
gates the outgrowth of the resistant tumor cells (Fig. S8). We
suspect that these mechanisms underlie the greater therapeutic
efﬁcacy of intermittent versus sustained p53 restoration. How-
ever, although an intermittent regimen of a p53-reactivating
treatment signiﬁcantly lengthened the lifespan of tumor-bearing
animals, we nonetheless detected tumors in all the intermittently
treated animals surviving beyond 100 d, and all animals from the
independent cohort left for surveillance following cessation of
intermittent treatment eventually succumbed to disease. Hence,
intermittent p53 restoration typically delays, rather than stops,
disease progression. As is consistent with this effect, the human
GBM cultures maintained under intermittent exposure to Prima-1
continue to proliferate once the drug is removed. These data
suggest that the application of therapy based on p53 restoration
in combination with other antiglioma strategies, for example
conventional GBM therapies such as temozolomide, will be more
beneﬁcial for patients than temozolomide alone. In particular,
patients with secondary GBMs exhibiting a high frequency of p53
mutations and displaying MGMT promoter silencing (46), which
is crucial for the tumor sensitivity to temozolomide (18), could be
regarded as ideal candidates. Nevertheless, our data predict
a signiﬁcant therapeutic advantage for intermittent versus sus-
tained regimens of p53-restoration therapy, making intermittent
therapy worthy of serious consideration in future clinical trial
designs involving p53-reactivating agents.
Materials and Methods
Mice and Tissue Sample Generation, Manipulation, and Preparation.Mice were
housed, fed, and treated in accordance with protocols approved by In-
stitutional Animal Care andUse Committee at theUniversity of California, San
Francisco. GFAP-V12HaRasIRESLacZ (GFAP-HRasV12) (RasD8) animals were
kindly provided by A. Guha (University of Toronto, Toronto) (29) and were
crossbred into the conditional p53 (p53KIKI) background (33) to generate
GFAP-HRasV12;p53+/+, GFAP-HRasV12;p53+/KI and GFAP-HRasV12;p53KI/KI prog-
eny. Hemizygous GFAP-HRasV12 animals were maintained on a mixed 129SvJ/
C57Bl6/CD1 background. Functionality of the p53ERTAM protein was restored
in vivo by i.p. injection of TAM (1mg/d) dissolved in peanut oil (Sigma). TAM is
metabolized to the ERTAM functional ligand 4-OHT in vivo, and our previous
studies conﬁrm the equivalent effects of TAM and 4-OHT when administered
to animals (33). Mice were sacriﬁced either when they exhibited symptoms of
neurological distress or at established time points. For irradiation studies,
mice were exposed to 7 Gy γ-radiation using a Mark 1–68 137Cesium source
(0.637 Gy/min). To inhibit MDM2 pharmacologically, mice were treated with
Nutlin-3 (Cayman Chemical) administered orally through gavage (200mg/kg),
initially 24 h before administration of 4-OHT and subsequently twice each day
during p53 restoration. Tissue samples were harvested 24 h after the ad-
ministration of 4-OHT. Brain tissues were embedded in Optimum Cutting
Temperature (OCT) medium (Sakura Finetek) or parafﬁn for immunohisto-
chemical and histological H&E analyses.
Histology and Immunoﬂuorescence. Analysis of tumor pathology was per-
formed on the H&E-stained 5-μm parafﬁn-embedded brain tissue sections.
Tumor grade was assigned using the World Health Organization grading
scheme (54). Inﬁltrating gliomas were considered grade III if they exhibited
mitotic ﬁgures in tumor cells. Identiﬁcation of tumor necrosis or endothelial
proliferation was sufﬁcient to categorize tumors as GBM-like. Areas with
increased proliferation but without the obvious nuclear pleomorphism or
other features of clearly neoplastic astrocytes were classiﬁed as “astrocyte
proliferation.” Such astrocyte proliferation was conﬁrmed by Ki67 staining.
For immunohistochemistry, 20-μm OCT-embedded brain tissue sections
were ﬁxed for 30 min in 1% paraformaldehyde solution. The following
primary antibodies were used: rabbit monoclonal anti-Ki67 (SP6; Neo-
markers), rabbit polyclonal anti–active-caspase 3 (AF 835; R&D), rat mono-
clonal anti-p19ARF (C3; Novus), mouse monoclonal anti-BrdU (11 299 964 001;
Roche), rat monoclonal anti-BrdU (OBT0030S; Accurate Chemicals), mouse
monoclonal anti-GFAP (610565; BD), and rabbit polyclonal anti-ER (MC-20,
SC-542; Santa Cruz). All antibodies were applied in blocking buffer [5%
(wt/vol) BSA, 2.5% (vol/vol) goat serum] for 2–16 h. Secondary antibodies
(Dako and Molecular Probes) were applied in blocking buffer for 1 h. TUNEL
staining was performed using the Apoptag ﬂuorescein-labeled kit (Chem-
icon) according to the manufacturer’s directions. Fluorescent images were
obtained using an LSM510 confocal microscope (Zeiss) or an Axiovert 100
inverted microscope (Zeiss) equipped with a Hamamatsu Orca digital cam-
era, running Open Lab 3.5.1 software (Improvision).
Immunoblotting. Primary mouse cell culture was performed as described in SI
Materials and Methods. Primary mouse tumor cultured cells and mouse
astrocytes were frozen as a cell pellet at −80 °C, lysed in buffer (50 mM Tris,
150 mM NaCl, 20 mM EDTA, 0.5% Nonidet P-40) supplemented with pro-
tease and phosphatase inhibitors, and centrifuged at 20,000 × g for 15 min
at 4 °C. Protein concentration was determined with the Bio-Rad protein
assay. Protein lysates were run in 4–20% gradient gels (Invitrogen) and were
blotted onto PVDF membranes (Immobilon-P). Membranes were probed
with anti-Mdm2 (SMP14; BD Pharmigen), p14ARF (4C6/4; Cell Signaling), and
anti–β-actin (AC-15; Sigma).
Taqman Analysis and p53 Sequencing Analysis on the Mouse Tumors. Total RNA
was isolated using TRIzol reagent (15596-018; Invitrogen) according to the
manufacturer’s protocol and DNase treated (18068–015; Invitrogen) before
reverse transcription (iScript; Bio-Rad). Taqman analysis was performed by
the University of California, San Francisco Comprehensive Cancer Center
Genome Analysis core facility. All data were normalized to β-glucuronidase (gus)
expression. The following probes were used: for mouse p21, Mm00432448_m1
(Applied Biosystems); for mouse PUMA, Mm00519268_m1 (Applied Biosystems);
and for mouse mdm2, Mm00487656_m1 (Applied Biosystems). For p53 se-
quencing analysis, cDNA was ampliﬁed with primers p53 forward: 5′-CCA TGG
AGGAGT CAC AGT CG-3′ and p53 reverse: 5′-GCA GAG GCA GTC AGT CTG AGT
C-3′ as described (37).
Human Glioma Cell Lines.Human glioma cell lines LN18 and LN215were kindly
provided by M. Hegi (University Hospital of Lausanne, Lausanne, Switzer-
land). U87MG was obtained from American Type Culture Collection. The p53
and p14ARF status in these cell lines was described previously (44). U87MG
has wild-type p53, LN215 has a p53 deletion 191–192, and LN18 has a p53
mutation at C238S. U87MG is p14ARF null, LN215 is p14ARF wild type, and
LN18 is p14ARF null. All cells were cultured in DMEM with 10% (vol/vol) FCS.
For analysis of tumor cell proliferation, glioma cell lines were plated at 3,000
cells per well in 96-well BD Falcon white/clear plates (353377; BD Bioscience)
and were cultured for 1, 3, and 5 d with 0, 5, 10, and 20 μM Prima-1 (Cayman
Chemical). Cell viability was analyzed by the Cell Titer GloR luminescent
assay (G7570; Promega). Experiments were done in triplicate.
To generate sustained and intermittent Prima-1–treated cell populations
of LN 215 cell cultures, LN 215 cells were cultured for 7 wk in the presence of
10 or 20 μM Prima-1. For weekly treatment, Prima-1 was added to the cells
for 24 once a week h. Twenty-four hours later the cells were washed once in
1× PBS, and fresh drug-free medium was added. For daily treatment, the
cells were exposed to Prima-1 continuously, and the medium containing
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Prima-1 was replaced three times a week. At the end of the treatment, the
cells were expanded in Prima-1–free medium for an additional week, and
proliferation and mRNA expression were analyzed as described above. Two
independent populations for each treatment were generated and analyzed.
Analysis of mRNA expression of p53 target genes in human GBM cell lines
was performed as described in SI Materials and Methods.
Statistical Analyses. Kaplan–Meier survival curves were generated using
GraphPad Prism5. The statistical analysis of the survival curves was done
according to the Mantel–Cox test. Tumor proliferation, apoptosis, and ex-
pression of p19ARF were quantiﬁed by MetaMorph Imaging V7.01 and
ImageJ software (National Institutes of Health). The statistical analysis was
carried out using a two-tailed Student t test. At least four animals were
analyzed for each treatment. Immunohistochemical analysis for each anti-
gen was performed at least in duplicate; 10 randomized ﬁelds per staining
were considered.
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SI Materials and Methods
Primary Mouse Cell Culture. Tumor tissues (identiﬁed based on high
cell density, morphology, and abundance of blood vessels) were
isolated using a stereo dissection microscope in ice cold 1×HBSS.
Tissues were washed and treated with papain (Worthington
Chemicals) for 30 min at 37 °C. Cells then were stained through
a 70-μm grid and were seeded onto laminin-coated six-well plates
for expansion. Primary coronal astrocytes were puriﬁed from
control p6-p10 GFAP-HRasV12 transgene-negative mice by disso-
ciation with papain, as described above, and were cultured in
Neurobasal medium (Invitrogen) supplemented with 2 mM L-
glutamine, B27 supplement, 20 ng/mL FGF-2, and 20 ng/mLEGF.
p53ERTAM was functionally restored in vitro by the addition
of 100 nM 4-OHT to the culture for the indicated period. Cell
number and viability were assessed by the trypan blue exclusion
method. For the irradiation experiment, cells were treated with
100 nM 4-OHT or vehicle (ethanol) for 2 h and were exposed to
7 Gy γ-radiation using a Mark 1–68 137Cesium source (0.637 Gy/
min). For in vitro MDM2 inhibition studies, cells were treated
with the indicated concentration of Nutlin-3 (Cayman Chemical)
or control vehicle (DMSO) for 2 h before restoration of p53 with
100 nM 4-OHT. The percentage of apoptotic cells was de-
termined by the trypan blue exclusion method. All experiments
were performed on three independently derived tumor cell cul-
tures and were performed in triplicate.
Primary Human Glioblastoma Cultures. Serially xenografted glio-
blastoma (GBM) 28, 14, and 43 cultures, originally isolated from
patients at Mayo Clinic, Minnesota, were kindly provided by
David James (University of California, San Francisco). Protein 53
(p53) status had been characterized previously in these cultures
(1). The p53 gene in GBM28 is mutated at M246T, GBM14 has
wild-type p53, and GBM43 has a p53 mutation at F270C. p14ARF
status also had been characterized previously in these cell lines:
GBM28 is p14ARF wild type, whereas both GBM14 and GBM43
are p14ARF-null (2). Human GBM cells were dissociated using
papain and were plated on ultra-low-adherent (Corning) or
polyornithine/laminin-coated plates and were cultured in Neu-
robasal medium (NBE) consisting of Neurobasal Medium-A,
0.5× B27 supplement, 0.5× N2 supplement (all reagents from
Invitrogen), 2 mM L-glutamine, penicillin/streptavidin, 20 ng/mL
basic FGF (Peprotech), and 20 ng/mL EGF (Sigma-Aldrich).
Media were changed every 3 d, and cells were passaged using
Accutase (Innovative Cell Technologies). Analysis of tumor cell
proliferation was performed as follows: dissociated human GBM
cells were plated at 3,000 cells per well in 96-well polyornithine/
laminin-coated plates in NBE medium and were cultured for 5 d
with 0 or 5 μM Prima-1 (Cayman Chemical). Cell numbers were
estimated using total DNA content as a guide by the Cyquant NF
proliferation assay (Invitrogen) according to the manufacturer’s
protocol. A standard curve was generated by plotting the number
of plated cells (1,000–40,000) against corresponding ﬂuorescent
values, resulting in the equation y = x +150, R2 = 1. The number
of cells in each sample was calculated using this equation. Ex-
periments were done in triplicate.
To analyze mRNA expression of p53 target genes in human
GBM cell lines, total RNA was isolated from the cell lines de-
scribed in Materials and Methods and treated with 0 or 5 μM of
Prima-1 for 24 h. To analyze mRNA expression of p53 target
genes in the primary human glioblastoma cultures described
above, the cultures were treated with 0 or 5 μM of Prima-1 for
5 d. The cDNA was synthesized with the iScript cDNA synthesis
kit (Bio-Rad) according to the manufacturer’s protocol. The ex-
pression analysis was performed with the RotorGene SybrGreen
PCR kit (Qiagen) on the RotorGeneQ and was analyzed with
RotorGeneQ series Software (Qiagen). The following primers
were used for the analysis: CDKN1A(p21) forward: 5′-TGT CCG
TCA GAA CCC ATG C-3′, reverse: 5′-AAA GTC GAA GTT
CCA TCG CTC-3′; mdm2 forward: 5′-TCG TCG GGT GAG
GGT ACT G-3′, reverse: 5′-AAC CAC TTC TTG GAA CCA
GGT-3′; gadd45a forward: 5′-GAG AGC AGA AGA CCG AAA
GGA-3′, reverse: 5′-CAG TGA TCG TGC GCT GAC T-3′. All
data were normalized to ribosomal protein L13a (RPL13A) and
β-actin expression. RPL13A forward: 5′-GCC ATC GTG GCT
AAA CAG GTA-3′, reverse: 5′-GTT GGT GTT CAT CCG
CTT GC-3′; β-actin forward: 5′-CAT GTA CGT TGC TAT
CCA GGC-3′, reverse: 5′-CTC CTT AAT GTC ACG CAC
GAT-3′. All analyses were done in triplicate.
Tumor Cell Transplantation Experiment. Tumor cells were harvested
from GFAP-Harvey Ras (HRas)V12;p53KI/KI [knock-in (KI)] ani-
mals and were cultured brieﬂy in NBE medium [Neurobasal-A
(Invitrogen), penicillin/streptavidin, 2 mM L-glutamine, B27
supplement (Invitrogen), 20 ng/mL FGF-2 (Peprotech), and 20
ng/mL EGF (Sigma-Aldrich)]. The tumor cells (8 × 104 in 10 μL
NBE medium) then were engrafted intracranially into anes-
thetized transgene-negative p53KI/KI littermates (1.5 mm lateral
and 2 mm posterior to the bregma and 3 mm deep) using
a Hamilton syringe and a stereotactic rig. Animals were moni-
tored daily for symptoms of glioma. A single injection of either
tamoxifen (TAM) or vehicle was administered i.p. to recipient
animals 3 wk after transplantation. Each cohort consisted of
seven animals, and the experiment was repeated twice with in-
dependently puriﬁed tumors.
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Fig. S1. Gliomas arising in GFAP-HRasV12;p53+/KI mice but not in GFAP-HRasV12;p53KI/KI mice lose upstream p53-activating pathways. (A) Immunohistochemical
analysis of p53ERTAM [estrogen receptor (ER)] allele expression in the brain tissue from tumor-bearing GFAP-HRasV12;p53+/KI animals. The normal brain tissue
(N) and tumor area (T) were determined by the density of tissue cellularity. The dotted lines demarcate the areas enlarged at right showing comparable
p53ERTAM allele expression in normal and tumor areas. Lateral ventricles (LV) are indicated. (Scale bars: 50 μm.) (B) Quantitative RT-PCR (qRT-PCR) analysis of
mRNA expression of the p53 target genes cyclin-dependent kinase inhibitor 1a (CDKN1A) (p21cip1), puma, and mouse double minute (mdm2) in tumor-derived
cell cultures from GFAP-HRasV12;p53+/KI animals after 24-h exposure to 4-hydroxytamoxifen (4-OHT) in vitro. Data are presented as fold induction relative to
control (vehicle-treated) samples. The data present experiments on three independently derived tumors, each analyzed in triplicate. (C) Immunohistochemical
analysis of cell death in GFAP-HRasV12;p53+/KI (Left) and GFAP-HRasV12;p53KI/KI (Right) tumors from animals treated with TAM for 2 h before exposure to 7-Gy
whole-body γ-radiation. Cell death is indicated by staining for activated caspase 3. The tumor boundary is indicated in the left panel. (Scale bars: 50 μm.) (D)
Percent of total tumor cell death in vitro of cultured glioma cells derived from GFAP-HRasV12;p53KI/KI animals after treatment with vehicle (Ctrl), restoration of
p53ERTAM allele for 24 h (4-OHT), and irradiation (7 Gy) in combination with vehicle treatment (Gy/CTRL) or p53 restoration (Gy/4-OHT). The data are derived
from three independently derived tumors, each analyzed in triplicate. (E) qRT-PCR analysis of mRNA expression of p53 target genes puma and CDKN1A in
cultured cancer cells derived from tumors from GFAP-HRasV12;p53KI/KI animals. Cells were exposed in vitro to γ-radiation in combination with 24-h exposure to
4-OHT (Gy/4-OHT) or vehicle (Gy/CTRL). The data are presented as fold induction relative to nonirradiated samples. The data represent experiments on three
independently derived tumors, each analyzed in triplicate. (F) Percent of total tumor cells undergoing apoptosis in control-treated (dark gray bars) or 4-OHT–
treated (light gray bars) tumor cell cultures derived from GFAP-HRasV12;p53KI/KI animals and after treatment in vitro with the MDM2 inhibitor Nutlin 3 at
concentrations of 16 (16 μM Ntl) or at 32 μM (32 μM Ntl) or with the vehicle for Nutlin treatment, DMSO. The data represent experiments on two tumor-cell
cultures independently derived from different tumor-bearing animals (T-288 and T-129, respectively), each analyzed in triplicate.
Fig. S2. Restoration of p53ERTAM function in GFAP-HRasV12;p53KI/KI tumor-bearing animals partially ablates tumors and reestablishes animal well-being.
Representative H&E analysis of tumors collected from GFAP-HRasV12;p53KI/KI animals treated with vehicle (p53ER-OFF) or TAM (p53ER-Restored) for 24 h. (Scale
bars: 20 μm.)
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Fig. S3. Gliomas arising in the absence of functional p53 retain the p53-activating pathway. (A) Immunoblotting analysis of Mdm2 expression in tumor-
derived cell cultures from GFAP-HRasV12;p53KI/+ and GFAP-HRasV12;p53KI/KI animals. Three independently derived GBM cultured cells of each genotype are
presented. β-Actin was used as an equal loading control. (B) Immunohistochemical analysis of p19ARF expression in GFAP-HRasV12;p53+/+, GFAP-HRasV12;p53KI/+,
and GFAP-HRasV12;p53KI/KI tumors. The location of the lateral ventricle (LV) is indicated, and the percentage of p19ARF-positive cells in tumors is shown below
the images. (Scale bars: 20 μm.)
Fig. S4. Gliomas arising during sustained restoration of p53 lack p19ARF expression in the actively proliferating cells. Immunohistochemical analysis of p19ARF
expression (green) in Ki67-positive cells (red) in control tumors (p53ER-OFF) and in tumors subjected to the sustained restoration of switchable p53 (p53ER-
Restored-Sustained). The star marks the location of the area enlarged in the Inset. Arrowheads point to p19ARF-positive cells in the p53ER-Restored-Sustained
tumors. At least four animals were analyzed for each treatment. Immunohistochemical analysis was performed in duplicate; 10 randomized ﬁelds per staining
were considered. The percentage of p19ARF-positive cells is indicated. (Scale bars: 20 μm.)
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Fig. S5. GFAP-HRasV12;p53KI/KI tumors transplanted intracranially into recipient mice retain p53-activating signals. (A) Survival curves (shown as days after
transplantation) of p53KI/KI animals transplanted with tumors derived from TAM-untreated (naive) GFAP-HRasV12;p53KI/KI mice. Because gliomas arise con-
tinuously in GFAP-HRasV12;p53KI/KI mice, it is reasonable to assume that the tumors emerging after single, transient restoration of p53ERTAM allele (presented in
Fig. 5B) are de novo tumors rather than recurring lesions. To address this point, primary tumors isolated from TAM-naive GFAP-HRasV12;p53KI/KI mice were
transplanted into p53KI/KI congenic recipients. Three weeks after the transplantation, animals were subjected to a single TAM treatment to restore p53 function
transiently (1× TAM, purple lines and circles) or to vehicle (CTRL, black lines and squares). (The arrowhead indicates the time point of the treatment after
transplantation.) The p53KI/KI animals transplanted with GFAP-HRasV12;p53KI/KI cancer cells succumb to recurring tumors after a single transient activation of
p53ERTAM allele. *P < 0.01. Statistical analyses were performed using the Mantel–Cox test. (B) Graph showing apoptotic tumor cells as a percentage of total
tumor cells determined by the TUNEL assay. Restoration of p53 function induces apoptosis in transplanted tumors recurring after 24-h restoration of the
p53ERTAM allele. The primary tumors (Primary) that develop in GFAP-HRasV12;p53KI/KI animals undergo apoptosis in response to a transient restoration of the
p53ERTAM allele by TAM (First Round; also see Fig. 3A). The tumors recurring after the ﬁrst round of a transient p53ERTAM restoration retain p53-activating
signals and die by apoptosis following a subsequent 24-h restoration of p53 (Second Round; also see Fig. 5B). The transplanted GFAP-HRasV12;p53KI/KI tumors
(Transplanted) that develop in recipient p53KI/KI animals also retain the p53-activating signals and respond by apoptotic cell death to a 24-h restoration of
p53ERTAM (First Round), and a subsequent 24-h restoration of p53 activity in recurring tumors described in Fig. S3A (Second Round). Five independent tumors
were analyzed for each data point. Ten randomized ﬁelds were analyzed.
Fig. S6. GFAP-HRasV12;p53KI/KI tumors recurring after a transient restoration of p53ERTAM retain p19ARF expression. Immunohistochemical analysis of p19ARF
and Ki67 in GFAP-HRasV12;p53KI/KI tumors that reemerge in animals after a single treatment with TAM (1x TAM) at age 3 wk compared with tumors from
animals subjected to weekly rounds of 24-h-long p53ERTAM restoration starting at age 3 wk (Intermittent TAM). Dotted lines indicate areas enlarged in Insets.
The percentage of total tumor cells positive for p19ARF/Ki67 is indicated. (Scale bars: 20 μm.)
Fig. S7. Restoration of p53 activity in human glioma cell lines. (A) Proliferation (presented as percent of control) of primary human cell lines (described in SI
Materials and Methods) with differential p53 and CDKN2A(ARF) status, mock-treated (dark gray bars) or treated with 20 μM Prima-1 (light gray bars) for 5 d.
MT, mutated. (B) The expression of p53 target genes CDKN1A(p21, mdm2, and growth arrest and DNA damage gene 45a (gadd45) in the primary human
glioma cell cultures after Prima-1 treatment is presented as the fold expression relative to the vehicle-treated control samples. The expression of the target
genes was normalized to ribosomal protein L13a (RLP13A) gene expression. The differential status of p53 and CDKN2A (ARF) is indicated. All analyses were
performed in triplicate.
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Fig. S8. Possible mechanisms behind the therapeutic advantage of intermittent versus sustained restoration of p53. (A) A schematic representation of the
growth advantage hypothesis that p19ARF-positive tumor cells have higher proliferating capacity than tumor cells lacking the p19ARF expression. (I) In the
presence of sustained activation of p53, p19ARF-negative tumor cells continue to proliferate and generate tumors resistant to subsequent p53 restoration. (II)
Upon single transient p53 restoration, the majority of p19ARF-positive cells undergo apoptosis and reversible growth arrest. The surviving p19ARF-positive cells
are capable of regenerating the tumor mass faster than their p19ARF-negative counterparts. (III) Further intermittent restoration of p53 in mostly p19ARF-
positive tumors results in p53-induced apoptosis and promotes survival of the tumor-bearing animals. (B) A schematic representation of the oncogene dosage
hypothesis that the tumor mass consists of cells expressing high and low levels of p19ARF depending on the level of rat sarcoma (Ras) oncogene activation. The
proliferation status of the cells expressing low levels of p19ARF is independent of p53 functionality as described by Murphy et al. (1). (I) Upon sustained res-
toration of p53, the cells expressing high levels of p19ARF undergo apoptosis or growth arrest in response to functional p53, whereas cells expressing low levels
of p19ARF continue to proliferate in a manner independent of p53 status. (II) Transient activation of p53 results in the elimination of the preexisting cells
expressing high levels of p19ARF. However, some of the preexisting p19ARF-negative cells might be converted to cells expressing high levels of p19ARF because of
an increase in Ras signaling or the accumulation of additional mutations. (III) The converted cells become sensitive to p53 restoration and can be targeted by
additional rounds of p53 treatment.
1. Murphy DJ, et al. (2008) Distinct thresholds govern Myc’s biological output in vivo. Cancer Cell 14(6):447–457.
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Movie S1. Live images of a symptomatic GFAP-HRasV12;p53KI/KI animal (ID#33782) taken 10 min before exposure to TAM.
Movie S1
Movie S2. Live images of a symptomatic GFAP-HRasV12;p53KI/KI animal (ID#33782) taken 7 d after exposure to TAM.
Movie S2
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